- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04775095
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (BLaDE)
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation (Secondary Data Use Study of Dabrafenib-Trametinib in "Real Life" for Non-Small Cell Lung Cancer With a BRAF V600 Mutation)
Study Overview
Status
Conditions
Detailed Description
The braf gene (V Raf murine sarcoma viral oncogene homolog, long arm of chromosome 7q3) codes for a protein (serine / threonine kinase) which regulates the signaling pathway RAS - RAF - MEK - ERK playing an important role in the proliferation processes, cell survival, angiogenesis, cell invasion and migration.
When activated by mutations, BRAF phosphorylates MEK to promote cell growth, proliferation and survival. In non-small cell lung cancer (NSCLC), BRAF mutations are found in 1-2% of cases. BRAF mutations are distinguished by kinase activity and their signaling via the mitogen-activated kinase (MAPK) pathway. BRAF V600 mutations, class I, signal as monomers with or without activated RAS. BRAF non-V600 are classified as either class II that signal as dimmers when RAS as activated or class III with impaired kinase activity but increased MAPK pathway signaling. The most frequent mutation in NSCLC (50% of cases) is the V600E mutation (glutamate / valine substitution, codon 600 of exon 15) which is activating (others mutations: G469A and D594G, respectively 39% and 11% of cases). One phase II trial demonstrated that the dabrafenib-trametinib combination had significant anti-tumor activity in terms of response rate, PFS in patients with a NSCLC with the BRAF V600E mutation, pretreated or not. In this multicentre non-randomized phase II open label study, a dabrafenib-trametinib combination was tested in 59 previously treated patients with metastatic stage IV BRAF V600E mutated NSCLC with documented progression after at least one prior platinum based chemotherapy. Overall response rate (ORR) was 63.2% (95% CI: 49.3 to 75.6%), median PFS was 9.7 months (95%CI 6.9-19.6). In the cohort of patients previously untreated (n=36) and treated with first line dabrafenib-trametinib combination, the investigator-assessed confirmed ORR was 64% (95% CI 46-79 %), the median investigator assessed PFS was 10.9 months (95CI:7-16.6) and the 6 month-PFS was 72% (53-84%) respectively.
At the last ASCO conference 2020, the data have been updated. In cohorts of untreated and previously treated patients, the ORR was 63.9% (95CI 46.2-79.2) and 68.4% (95CI 54.8, 80.1), median PFS 10.8 months (95CI 7.0-14.5) and 10.2 months (95CI: 6.9-16.7). Median OS was 17.3 months (95% CI: 12.3-40.2; 3 years OS: 40%) and 18.2 months (95% CI: 14.3-28.6; 3 years OS: 33%) with 14/36 and 11/57 patients alive in treatment naïve and pretreated patients respectively.
The dabrafenib-trametinib combination had European authorization since 2017. In January 2020, the French Transparency Committee validated its possible use in second line in current practice, after failure of a first therapeutic line (whatever its nature) but only for BRAF V600E mutations. Clinical outcomes data on BRAF-mutated V600 NSCLC patients treated in routine practice by dabrafenib-trametinib combination is limited with only retrospective studies including few patients.
The primary objective of this retrospective multicenter observational study is to describe, in real world, the characteristics and evolution of NSCLC patients with a BRAF V600 E mutation treated with the dabrafenib-trametinib combination regardless of the line of treatment. Also, this retrospective multicenter observational will describe in real world, the characteristics, treatment and evolution of NSCLC patients with a BRAF V600 non E mutation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Créteil, France
- Créteil - CHI
-
Lyon, France
- Lyon - CRLCC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with histologically or cytologically confirmed extensive stage NSCLC
- Presence of BRAF V 600 E or non E mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) between 01/01/2016 and 31/12/2019
- Patients who received at least one dose of treatment with dabrafenib-trametinib combination (whatever the treatment line)
- NSCLC BRAF V600 patients who have not received the dabrafenib-trametinib combination will be included for the collection of clinical and demographic data, treatments received and OS
- Patients who were informed about the study and do not refused for their data to be collected and used
- Age > 18 years
Exclusion Criteria:
- Patients harboring a non V600 BRAF mutation
- Patients enrolled in a clinical trial assessing treatment with dabrafenib-trametinib combination
- Explicit refusal by the patient to collect his or her data
- Patients under curatorship or guardianship
- Unable to obtain data collection
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS) at 12 months in non-small cell lung cancer (NSCLC) BRAF V600E-mutated patients receiving the combination of dabrafenib-trametinib as second line or more treatment
Time Frame: 12 months
|
OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS at 18 and 24 months and median OS in NSCLC BRAF V600E-mutated patients receiving the combination of dabrafenib-trametinib as second line or more treatment
Time Frame: 18 and 24 months
|
OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
|
18 and 24 months
|
OS at 12, 18 and 24 months and median OS in NSCLC BRAF V600E-mutated patients receiving the combination of dabrafenib-trametinib as first-line treatment
Time Frame: at 12, 18 and 24 months
|
OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
|
at 12, 18 and 24 months
|
OS at 12, 18 and 24 months and median OS in NSCLC BRAF V600E-mutated patients regardless of the treatment received
Time Frame: at 12, 18 and 24
|
OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
|
at 12, 18 and 24
|
OS at 12, 18 and 24 months and median OS in NSCLC BRAF V600E-mutated patients not treated by the combination of dabrafenib-trametinib, according to the treatment and the line received
Time Frame: at 12, 18 and 24
|
OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
|
at 12, 18 and 24
|
OS at 12 months and median OS in NSCLC BRAF V600 non E-mutated patients according to the treatment and the line received
Time Frame: at 12 months
|
OS will be determined as the time from the first dose of treatment with dabrafenib-trametinib to death from any cause
|
at 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Jean-Bernard AULIAC, Dr, Créteil -CHI
- Study Chair: Aurélie SWALDUZ, Dr, Lyon - CLCC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IFCT-2004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States